BridGene Biosciences
- Business Model
- B2B
- Website
- bridgenebio.com
- Total Funding
- $80.5M
- Last Round
- $28.0M Series BOct 2025
- Rounds
- 3
About
Chemoproteomics-driven small-molecule drug R&D for undruggable targets
Summary
BridGene Biosciences is a Biotech company. It has raised $80.5M in total across 3 rounds, most recently a $28.0M Series B round in Oct 2025. Investors include Lapam Capital, Bayland Capital and Proxima Ventures.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company